Guidance A-Z — C
179 guidance documents beginning with C.
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabotegravir for preventing HIV-1 in adults and young people
Cabotegravir with rilpivirine for treating HIV-1
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine
Cabozantinib for previously treated advanced hepatocellular carcinoma
Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib for treating medullary thyroid cancer
Cabozantinib for untreated advanced renal cell carcinoma
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma
CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease
Caesarean birth
Caesarean birth
Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)
Canagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over
Cancer services for children and young people
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)
Cannabidiol for treating seizures caused by tuberous sclerosis complex
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Cannabis-based medicinal products
Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer
Capecitabine for the treatment of advanced gastric cancer
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)
Cardiac contractility modulation device implantation for heart failure
Cardiovascular disease prevention
Cardiovascular disease: identifying and supporting people most at risk of dying early
Cardiovascular disease: risk assessment and reduction, including lipid modification
Cardiovascular risk assessment and lipid modification
Care and support of people growing older with learning disabilities
Care of dying adults in the last days of life
Care of dying adults in the last days of life
CareLink network service for remote monitoring of people with cardiac devices
Carfilzomib for previously treated multiple myeloma
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessment
Caris Molecular Intelligence for guiding cancer treatment
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)
Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias
Carotid artery stent placement for symptomatic extracranial carotid stenosis
Cataracts in adults: management
Catheterless oesophageal pH monitoring
Caval valve implantation for tricuspid regurgitation
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections
Cellulitis and erysipelas: antimicrobial prescribing
Cellvizio confocal endomicroscopy system for characterising pancreatic cysts
Cemiplimab for treating advanced cutaneous squamous cell carcinoma
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
Cenobamate for treating focal onset seizures in epilepsy
CentriMag for heart failure
CerebAir for continuous EEG monitoring in intensive care
Cerebral palsy in adults
Cerebral palsy in adults
Cerebral palsy in children and young people
Cerebral palsy in under 25s: assessment and management
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib for untreated ALK-positive non-small-cell lung cancer
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic
Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges
Child abuse and neglect
Child abuse and neglect
Child maltreatment: when to suspect maltreatment in under 18s
Children's attachment
Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
Chronic heart failure in adults
Chronic heart failure in adults: diagnosis and management
Chronic kidney disease in adults
Chronic kidney disease: assessment and management
Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing
Chronic obstructive pulmonary disease in adults
Chronic obstructive pulmonary disease in over 16s: diagnosis and management
Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
Cirrhosis in over 16s: assessment and management
Cladribine for treating active relapsing forms of multiple sclerosis
Cladribine for treating relapsing–remitting multiple sclerosis
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)
Cabotegravir for preventing HIV-1 in adults and young people
Cabotegravir with rilpivirine for treating HIV-1
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine
Cabozantinib for previously treated advanced hepatocellular carcinoma
Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib for treating medullary thyroid cancer
Cabozantinib for untreated advanced renal cell carcinoma
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma
CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease
Caesarean birth
Caesarean birth
Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)
Canagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over
Cancer services for children and young people
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)
Cannabidiol for treating seizures caused by tuberous sclerosis complex
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Cannabis-based medicinal products
Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer
Capecitabine for the treatment of advanced gastric cancer
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)
Cardiac contractility modulation device implantation for heart failure
Cardiovascular disease prevention
Cardiovascular disease: identifying and supporting people most at risk of dying early
Cardiovascular disease: risk assessment and reduction, including lipid modification
Cardiovascular risk assessment and lipid modification
Care and support of people growing older with learning disabilities
Care of dying adults in the last days of life
Care of dying adults in the last days of life
CareLink network service for remote monitoring of people with cardiac devices
Carfilzomib for previously treated multiple myeloma
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessment
Caris Molecular Intelligence for guiding cancer treatment
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)
Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias
Carotid artery stent placement for symptomatic extracranial carotid stenosis
Cataracts in adults: management
Catheterless oesophageal pH monitoring
Caval valve implantation for tricuspid regurgitation
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections
Cellulitis and erysipelas: antimicrobial prescribing
Cellvizio confocal endomicroscopy system for characterising pancreatic cysts
Cemiplimab for treating advanced cutaneous squamous cell carcinoma
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
Cenobamate for treating focal onset seizures in epilepsy
CentriMag for heart failure
CerebAir for continuous EEG monitoring in intensive care
Cerebral palsy in adults
Cerebral palsy in adults
Cerebral palsy in children and young people
Cerebral palsy in under 25s: assessment and management
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib for untreated ALK-positive non-small-cell lung cancer
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic
Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges
Child abuse and neglect
Child abuse and neglect
Child maltreatment: when to suspect maltreatment in under 18s
Children's attachment
Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
Chronic heart failure in adults
Chronic heart failure in adults: diagnosis and management
Chronic kidney disease in adults
Chronic kidney disease: assessment and management
Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing
Chronic obstructive pulmonary disease in adults
Chronic obstructive pulmonary disease in over 16s: diagnosis and management
Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
Cirrhosis in over 16s: assessment and management
Cladribine for treating active relapsing forms of multiple sclerosis
Cladribine for treating relapsing–remitting multiple sclerosis
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)
12